Lapse of subscription agreement in relation to the issue of h shares under general mandate

Reference is made to the announcements of TYK Medicines, Inc (the “Company”) dated July 21, 2026 and August 20, 2026 (the “Announcements”) regarding the license and collaboration with Qilu and the proposed issuance of 63,222,744 H Shares to the Subscriber. Unless otherwise defined, capitalised terms used in this announcement shall have the same meanings as those defined in the Announcements. As di